Chapter 2 —— 27 —— References 1. Cornu, T.I.; Mussolino, C.; Cathomen, T.. Refining strategies to translate genome editing to the clinic. Nat. Med. 2017, 23, 415–423. 2. Wang, J.Y.; Doudna, J.A.. CRISPR technology: a decade of genome editing is only the beginning. Science 2023, 379, eadd8643. 3. Finck, A.V.; Blanchard, T.; Roselle, C.P.; Golinelli, G.; June, C.H.. Engineered cellular immunotherapies in cancer and beyond. Nat. Med. 2022, 28, 678–689. 4. Sahillioglu, A.C.; Schumacher, T.N.. Safety switches for adoptive cell therapy. Curr. Opin. Immunol. 2022, 74, 190–198. 5. Chen, X.; Gonçalves, M.A.F.V.. DNA, RNA, and protein tools for editing the genetic information in human cells. iScience 2018, 6, 247–263. 6. Huang, X.; Yang, D.; Zhang, J.; Xu, J.; Chen, Y.E.. Recent advances in improving gene-editing specificity through CRISPR-Cas9 nuclease engineering. Cells 2022, 11, 2186. 7. Jang, H.K.; Song, B.; Hwang, G.H.; Bae, S.. Current trends in gene recovery mediated by the CRISPR-Cas system. Exp. Mol. Med. 2020, 52, 1016–1027. 8. Holkers, M.; Maggio, I.; Henriques, S.F.; Janssen, J.M.; Cathomen, T.; Gonçalves, M.A.. Adenoviral vector DNA for accurate genome editing with engineered nucleases. Nat. Methods 2014, 11, 1051–1057. 9. He, X.; Tan, C.; Wang, F.; et al. Knock-in of large reporter genes in human cells via CRISPR/Cas9-induced homology-dependent and independent DNA repair. Nucleic Acids Res. 2016, 44: e85. 10. Globerson Levin, A.; Riviere, I.; Eshhar, Z.; Sadelain. M.. CAR T cells: building on the CD19 paradigm. Eur. J. Immunol. 2021, 51, 2151–2163. 11. Detela, G.; Lodge, A.. EU regulatory pathways for ATMPs: standard, accelerated and adaptive pathways to marketing authorisation. Mol. Ther. Methods Clin. Dev. 2019, 13, 205–232. 12. Ivica, N.A.; Young C.M.. Tracking the CAR-T revolution: analysis of clinical trials of CAR-T and TCR-T therapies for the treatment of cancer (1997–2020). Healthcare (Basel) 2021, 9, 1062. 13. Vogler, M.; Shanmugalingam, S.; Sarchen. V.; et al. Unleashing the power of NK cells in anticancer immunotherapy. J. Mol. Med. (Berl.) 2022, 100, 337–349. 14. Muller, T.R.; Jarosch, S.; Hammel, M.; et al. Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapy. Cell Rep. Med. 2021, 2, 100374. 15. Pavani, G.; Amendola, M.. Targeted gene delivery: where to land. Front. Genome Ed.
RkJQdWJsaXNoZXIy MTk4NDMw